BACKGROUND: Experimental studies indicate that arginine vasopressin (AVP) may have deleterious effects in the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD). However, the significance of AVP in human ADPKD is unclear. STUDY DESIGN: Longitudinal observational study with 8.5 (IQR, 7.7-9.0) years' follow-up (CRISP [Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease]). SETTING & PARTICIPANTS: 241 patients with ADPKD with creatinine clearance >70 mL/min. PREDICTOR: Plasma copeptin concentration, a surrogate marker for AVP. OUTCOMES: Change in measured glomerular filtration rate (mGFR, assessed by iothalamate clearance) and total kidney volume (measured by magnetic resonance imaging). MEASUREMENTS: Baseline copeptin level, plasma and urinary osmolality, and measurements of total kidney volume and mGFR during follow-up. RESULTS: In these patients (median age, 34 [IQR, 25-40] years; 38% men; median mGFR, 94 [IQR, 79-145] mL/min/1.73 m(2); median total kidney volume, 859 [IQR, 577-1,299] mL), median copeptin level was 2.9 (IQR, 1.8-5.1) pmol/L. Copeptin was not associated with plasma osmolality (P = 0.3), the physiologic stimulus for AVP release, but was associated significantly with change in total kidney volume during follow-up (P < 0.001). This association remained significant after adjusting for sex, age, cardiovascular risk factors, and diuretic use (P = 0.03). Copeptin level was associated borderline significantly with change in mGFR after adjusting for these variables (P = 0.09). LIMITATIONS: No standardization of hydration status at time of copeptin measurement. CONCLUSIONS: These data show that in ADPKD, copeptin level, as a marker for AVP, is not correlated with plasma osmolality. Most importantly, high copeptin levels are associated independently with disease progression in early ADPKD. This is in line with experimental studies that indicate a disease-promoting role for AVP.
BACKGROUND: Experimental studies indicate that arginine vasopressin (AVP) may have deleterious effects in the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD). However, the significance of AVP in humanADPKD is unclear. STUDY DESIGN: Longitudinal observational study with 8.5 (IQR, 7.7-9.0) years' follow-up (CRISP [Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease]). SETTING & PARTICIPANTS: 241 patients with ADPKD with creatinine clearance >70 mL/min. PREDICTOR: Plasma copeptin concentration, a surrogate marker for AVP. OUTCOMES: Change in measured glomerular filtration rate (mGFR, assessed by iothalamate clearance) and total kidney volume (measured by magnetic resonance imaging). MEASUREMENTS: Baseline copeptin level, plasma and urinary osmolality, and measurements of total kidney volume and mGFR during follow-up. RESULTS: In these patients (median age, 34 [IQR, 25-40] years; 38% men; median mGFR, 94 [IQR, 79-145] mL/min/1.73 m(2); median total kidney volume, 859 [IQR, 577-1,299] mL), median copeptin level was 2.9 (IQR, 1.8-5.1) pmol/L. Copeptin was not associated with plasma osmolality (P = 0.3), the physiologic stimulus for AVP release, but was associated significantly with change in total kidney volume during follow-up (P < 0.001). This association remained significant after adjusting for sex, age, cardiovascular risk factors, and diuretic use (P = 0.03). Copeptin level was associated borderline significantly with change in mGFR after adjusting for these variables (P = 0.09). LIMITATIONS: No standardization of hydration status at time of copeptin measurement. CONCLUSIONS: These data show that in ADPKD, copeptin level, as a marker for AVP, is not correlated with plasma osmolality. Most importantly, high copeptin levels are associated independently with disease progression in early ADPKD. This is in line with experimental studies that indicate a disease-promoting role for AVP.
Authors: Wendy E Boertien; Esther Meijer; Debbie Zittema; Marjan A van Dijk; Ton J Rabelink; Martijn H Breuning; Joachim Struck; Stephan J L Bakker; Dorien J M Peters; Paul E de Jong; Ron T Gansevoort Journal: Nephrol Dial Transplant Date: 2012-04-20 Impact factor: 5.992
Authors: Franck A Belibi; Gail Reif; Darren P Wallace; Tamio Yamaguchi; Lincoln Olsen; Hong Li; George M Helmkamp; Jared J Grantham Journal: Kidney Int Date: 2004-09 Impact factor: 10.612
Authors: Bernard F King; Vicente E Torres; Marijn E Brummer; Arlene B Chapman; Kyongtae T Bae; James F Glockner; Kraisthith Arya; Joel P Felmlee; Jared J Grantham; Lisa M Guay-Woodford; William M Bennett; Saulo Klahr; Gladys H Hirschman; Paul L Kimmel; Paul A Thompson; J Phillip Miller Journal: Kidney Int Date: 2003-12 Impact factor: 10.612
Authors: Vicente E Torres; Xiaofang Wang; Qi Qian; Stefan Somlo; Peter C Harris; Vincent H Gattone Journal: Nat Med Date: 2004-02-29 Impact factor: 53.440
Authors: Fouad T Chebib; Caroline R Sussman; Xiaofang Wang; Peter C Harris; Vicente E Torres Journal: Nat Rev Nephrol Date: 2015-04-14 Impact factor: 28.314
Authors: Michel Chonchol; Berenice Gitomer; Tamara Isakova; Xuan Cai; Isidro Salusky; Renata Pereira; Kaleab Abebe; Vicente Torres; Theodor I Steinman; Jared J Grantham; Arlene B Chapman; Robert W Schrier; Myles Wolf Journal: Clin J Am Soc Nephrol Date: 2017-07-13 Impact factor: 8.237
Authors: Ray El Boustany; Irina Tasevska; Esther Meijer; Lyanne M Kieneker; Sofia Enhörning; Guillaume Lefèvre; Kamel Mohammedi; Michel Marre; Frédéric Fumeron; Beverley Balkau; Nadine Bouby; Lise Bankir; Stephan Jl Bakker; Ronan Roussel; Olle Melander; Ron T Gansevoort; Gilberto Velho Journal: JCI Insight Date: 2018-07-12
Authors: Ron T Gansevoort; Maatje D A van Gastel; Arlene B Chapman; Jaime D Blais; Frank S Czerwiec; Eiji Higashihara; Jennifer Lee; John Ouyang; Ronald D Perrone; Katrin Stade; Vicente E Torres; Olivier Devuyst Journal: Kidney Int Date: 2019-03-09 Impact factor: 10.612
Authors: Robert W Schrier; Godela Brosnahan; Melissa A Cadnapaphornchai; Michel Chonchol; Keith Friend; Berenice Gitomer; Sandro Rossetti Journal: J Am Soc Nephrol Date: 2014-06-12 Impact factor: 10.121
Authors: Debbie Zittema; Else van den Berg; Esther Meijer; Wendy E Boertien; Anneke C Muller Kobold; Casper F M Franssen; Paul E de Jong; Stephan J L Bakker; Gerjan Navis; Ron T Gansevoort Journal: Clin J Am Soc Nephrol Date: 2014-07-03 Impact factor: 8.237